Machine learning models have shown promise in advancing gastrointestinal clinical research, addressing unmet needs, and laying the foundation for future innovations in drug development and endpoint evaluation.
CAMBRIDGE, Mass., Oct. 24, 2024–(BUSINESS WIRE)–Iterative Health, a technology and services company dedicated to advances in gastrointestinal care, is co-sponsoring the American College of Gastroenterology 2024 with leading research institutions. We will present new data at our annual meeting. Academic researchers and life science partners. Five summaries highlight the potential of advanced machine learning (ML) algorithms to address shortcomings of current approaches to endoscopic assessment of inflammatory bowel disease (IBD) in clinical trials and routine practice.
“There is a need to innovate traditional endoscopic assessments used in gastrointestinal research to improve the accuracy of efficacy measurements in clinical trials,” said Dr. David T. Rubin, director of the Center for Inflammatory Bowel Disease at the University of Chicago Medicine. It’s clear that there is,” he said. “Ongoing research with Iterative Health shows the invaluable potential of the company’s machine learning tools to improve endoscopic assessment, thereby enhancing the drug development process and ultimately improving long-term patient outcomes.” It shows the possibility.”
The research presented at ACG will demonstrate the potential of ML applications to address gaps in current approaches to endoscopic evaluation in IBD research, with a focus on ulcerative colitis. The abstract collection provides an unprecedented comparison of two ML models and an overview of a new real-world dataset linking AI-assessed endoscopic disease severity to electronic health record (EHR) data. Included.
“Given the complexity of conducting gastrointestinal clinical trials, there is a significant opportunity to leverage technology to drive more effective and efficient clinical research that yields deeper insights into disease activity.” said Dr. Vijay Yajnik, the bureau’s vice president and chief of gastroenterology. ,Takeda. “The goal of our partnership with Iterative Health is to facilitate more evidence-based decision-making regarding treatment utilization in the real world, ultimately moving us one step closer to precision medicine in IBD.”
Iterative Health leverages advanced technology and data analytics to streamline gastrointestinal research and support drug development and post-market strategies. This approach aims to provide more objective measures of disease severity and treatment response, increasing the efficiency and accuracy of clinical research.
“At Iterative Health, we are leveraging a scientific approach to show how machine learning can transform the research and development of new treatments,” said Shuljal Bakshi, Ph.D., MPH, Chief Medical Officer, Iterative Health. says. “We are focused on evolving traditional endpoints, such as endoscopic scoring, to provide new actionable insights. We are collaborating with industry partners to generate and present new data. This is an important step in our long-term strategy to shift the paradigm of evidence generation in gastrointestinal diseases. ”
story continues
For more information about Iterative Health’s presentation at ACG 2024, visit https://acgmeetings.gi.org/.
About recurrent health
Iterative Health is a healthcare technology and services company with a mission to provide timely access to higher standards of gastrointestinal care. With deep expertise in artificial intelligence and clinical research, we enable healthcare professionals to consistently deliver high-quality colorectal cancer screening, and clinical research teams and study sponsors to increase patient access to new treatments. We help you expand and accelerate access. The company is headquartered in Cambridge, Massachusetts, with offices throughout the United States. For more information, visit www.iterative.health and follow us on LinkedIn. × See the latest company information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024961612/en/
contact address
media contact
Andrea Sampson, Sampson Public Relations Group
asampson@sampsonprgroup.com
